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Abstract
Background: Antibiotic therapy should be done based on resistance characteristics of Helicobacter pylori strains to commonly pre-
scribed antibiotics in areas with higher resistance rates.
Objectives: This study examined antibacterial activity of nitazoxanide and doxycycline against clinical H. pylori isolates showing
different metronidazole resistance levels.
Methods: A total of 122 patients, who underwent endoscopy were enrolled in this study from 3 hospitals of Tehran, during Novem-
ber 2014 to July 2015. Helicobacter pylori isolates were obtained from gastric biopsies of the patients after culture in specific culture
medium and characterization by both biochemical and molecular methods. Antimicrobial susceptibility to metronidazole was de-
tected using the agar dilution method and minimum inhibitory concentrations of nitazoxanide and doxycycline were determined
for metronidazole resistant strains.
Results: From a total of 122 gastric biopsy specimens, 55 H. pylori strains were recovered (45%). Thirty-three of these strains (60.0%)
were resistance to metronidazole. MIC50 and MIC90 values for metronidazole were 32 and 64 µg/mL, respectively. MIC50 and MIC90
values for doxycycline and nitazoxanide were measured as 4 and≥8µg/mL, and 8 and≥32µg/mL, respectively.
Conclusions: Dominance of high level metronidazole resistance H. pylori strains among the studied patients questioned its useful-
ness for first-line therapy in Iran. Nitazoxanide and doxycycline showed superior activity against H. pylori strains in comparison to
metronidazole, which should be considered for alternative therapies.
Keywords: Antibiotic Resistance, Metronidazole, Doxycycline, Nitazoxanide, Minimum Inhibitory Concentration, Helicobacter
Pylori
1. Background
Helicobacter pylori, spiral Gram negative and mi-
croaerophilic bacteria, are present in the gastric mucosa
of most of the world’s population (1). They were intro-
duced as a class I carcinogenic agent in 1994 by the world
health organization (WHO) (1). These bacteria induce
chronic inflammation leading to chronic gastritis, gastric
ulcer, duodenal ulcer, and ultimately cancer (2). They are
rapidly becoming resistant to most antibiotics used in
therapeutic regimens.
The extent of antibiotic resistance patterns varies in
different geographical regions, which is a direct reflec-
tion of the antibiotic regimens used in each region (3).
The most common regimen includes a bismuth salt along
with 2 of the following antibiotics: metronidazole, amox-
icillin, clarithromycin or tetracycline. However, antibi-
otic resistance is becoming very prevalent in developing
countries. Antibiotic resistance is assumed to be the main
reason of eradication failure in H. pylori infected patients
(4). Since metronidazole is the most common antibiotic
used, especially in developing countries, metronidazole
resistance reduces treatment adequacy by 50% in these
areas (5). The high level resistance to this drug has led
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to elimination of many first line antibiotics (6). Differ-
ent alternative regimens are now proposed for empirical
first line therapy against H. pylori infection in high clar-
ithromycin and metronidazole resistance areas. Nitazox-
anide and doxycycline are 2 antibiotics that their use to-
gether with quinolones was suggested as a successful al-
ternative therapy (7). Nitazoxanide, a benzamide thia-
zolide derivative, has been shown to be effective against
many bacteria as well as helminthes and protozoa (8-10).
It is believed to act through interference with pyruvate
metabolism, which seems to be required for anaerobic cell
energy metabolism (8). Doxycycline, which is a synthetic
tetracycline derivative is absorbed more easily with food
and has a much simpler dosing schedule (11). Adverse side-
effects of doxycycline is lower than the numerous side-
effects of tetracycline, such as tooth discoloration, gas-
trointestinal symptoms, candidiasis, and photosensitivity
(11-14). Due to the worldwide high prevalence of metron-
idazole resistance H. pylori strains, this study sought to
determine the in vitro effectiveness of nitazoxanide and
doxycycline against metronidazole resistant isolates at dif-
ferent concentrations.
2. Objectives
This study aimed at investigating antibiotic resistance
patterns of metronidazole resistant H. pylori strains to
doxycycline and nitazoxanide.
3. Methods
3.1. Patients, Sample Collection and Culture
This cross sectional study was undertaken at 3 general
hospitals of Tehran from November 2014 to July 2015. He-
licobacter pylori strains were isolated from 122 biopsy spec-
imens obtained from patients with gastrointestinal com-
plaints during endoscopy. Three biopsies were obtained
from antrum of stomach by a gastroenterologist, which
were used for pathological analysis and examination of
urease activity and culture. One of the samples was im-
mediately transferred to the laboratory in thioglycolate
medium (MERCK, Germany) for culture. The sample was
subsequently processed for bacterial culture in Brucella
agar medium supplemented with 10% horse blood, 10% fe-
tal bovine serum, amphotericin B (10 mg, Sigma-Aldrich,
USA), and Campylobacter selective supplement consisting
of vancomycin 2.0 mg, polymyxin 0.05 mg, and trimetho-
prim 1.0 mg (Merck, Homburg, Germany). The plates were
incubated at microaerophilic atmosphere (%8 N2, %5 CO2,
%8 - 10% O2) in a Gas Pak jar for 3 to 5 days. Exclusion cri-
teria included treatment with proton pump inhibitor and
use of antibiotics during the two last weeks prior to sample
collection.
3.2. Isolation and Characterization of Helicobacter pylori
Strains
Grown colonies of bacteria were examined macroscop-
ically and biochemically. Small shiny colonies that showed
positive urease, catalase, and oxidase tests were collected
and preserved at -20°C for molecular identification using
species specific primers. Freshly grown colonies of the bac-
terial isolates were subjected to QIAamp tissue DNA extrac-
tion kit, according to the manufacturer’s instructions (Qi-
agen, Hilden, Germany). Polymerase Chain Reaction was
performed by primer targeting glmM (ureC), which ampli-
fied a 296-bp fragment based on PCR conditions, as de-
scribed by Shahabimehr et al. (14).
3.3. Determination of Minimum Inhibitory Concentrations
To measure the lowest inhibitory concentrations of the
antibiotics forH. pylori strains, minimal inhibitory concen-
trations were determined by the agar dilution method, ac-
cording to the CLSI guidelines (15). Accordingly, a suspen-
sion with a turbidity equivalent to that of a McFarland No.2
standard (approximately 6 × 108 bacteria/mL) was pre-
pared from a 48-hour culture on agar plates. Susceptibil-
ity testing was performed on Mueller Hinton agar medium
containing horse blood (10%) and appropriate dilution
of metronidazole (0.5 to 64 µg/mL). Following prepara-
tion of microbial suspension, inoculation took place in
plates containing different concentrations of metronida-
zole by spotting 10 µL of the bacterial suspension. Within
a short space of time after the absorption of the samples,
plates were incubated under microaerophilic conditions
for 2 days at 37°C. Minimum inhibitory concentration was
determined as the lowest concentration of antimicrobial
agent inhibiting the total growth of bacteria. Resistance
was considered when the metronidazole MIC was greater
than 8 µg/mL (Eucast, version 2.0). After identification
of metronidazole resistant isolates, the resistant strains
were tested for determination of the MIC values of doxy-
cycline and nitazoxanide. The same protocol was used for
determination of MIC values of nitazoxanide and doxycy-
cline, except the bacterial turbidity that was set at McFar-
land No.3 standard (approximately 6 × 109 bacteria/mL)
for nitazoxanide. Doxycycline concentrations ranged from
0.12 to 8 µg/mL and nitazoxanide concentrations ranged
from 0.03 to 32.0 µg/mL. Minimum inhibitory concentra-
tion values at which 50% and 90% of the tested strains
were inhibited, were reported as MIC50 and MIC90, respec-
tively. Dimethyl sulfoxide was used as the solvent for pro-
viding defined concentrations of doxycycline and nitazox-
anide. Metronidazole, doxycycline, and nitazoxanide were
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obtained from Sigma Company (USA). Since there were no
acceptable breakpoints for interpretation of nitazoxanide
and doxycycline resistance for H. pylori strains, MIC values
were reported for these two antibiotics. Helicobacter pylori
strain RIGLD OC218 was used as a control strain in all exper-
iments.
3.4. Statistical Analysis
Results of the demographic information and values
of MICs of antibiotics were analyzed using the SPSS 18
software (SPSS, Chicago, IL, USA). Also, chi-square test and
Fisher’s exact test were used to analyze the data. A p value
of≤0.05 was considered statistically significant for differ-
ences.
4. Results
4.1. Helicobacter pylori Infection
Out of 122 gastric biopsy specimens, 55 H. pylori iso-
lates were collected (45%). Identity of all the isolates was
confirmed as H. pylori by both biochemical and molecular
methods. The mean age of infected patients was 49 years
(males: 49% and females: 51%). No significant difference
was detected in the infection rate between males and fe-
males (54.5%, 30/55 and 45.4%, 25/55, respectively). Patho-
logical findings showed occurrence of chronic gastritis
(58%), severe active gastritis (30%), and intestinal metapla-
sia (12%) in these patients.
4.2. Quantitative Method
There was no significant correlation between MIC val-
ues of 3 antibiotics and pathological findings.
4.3. Antibiotic Susceptibility Testing
Results of antibiotic susceptibility testing showed
a frequency of 60% (33/55) for metronidazole resistant
H.pylori strains (MIC > 8µg/mL). The MIC values of metron-
idazole for the H. pylori strains are shown in Table 1.
The MIC50 and MIC90 values for metronidazole were
32 and 64 µg/mL, respectively. In the case of doxycycline,
its MIC values ranged between 1 and≥8 µg/mL. The MIC50
and MIC90 values for doxycycline were measured as 4 and
≥8 µg/mL, respectively (Table 1). The MIC values for ni-
tazoxanide in the metronidazole resistant H. pylori were
in ranges of 1 to ≥32 µg/mL. The MIC50 and MIC90 values
for nitazoxanide were determined as 8 and≥32µg/mL, re-
spectively. Diversity of MIC values of doxycycline and ni-
tazoxanide for all of the metronidazole resistant strains
is shown in Figure 1. In general, higher activity of nita-
zoxanide and doxycycline was detected against metronida-
zole resistance H. pylori strains. Although H. pylori strains
with an MIC value of ≥32 µg/mL for metronidazole were
mainly inhibited with lower concentrations of nitazox-
anide and doxycycline, this correlation was not found for
the strains with lower MIC values (8 to 16 µg/mL). Accord-
ingly, some of the metronidazole resistant strains with MIC
values of ≥8 µg/mL were not inhibited by highest exam-
ined concentrations of these 2 antibiotics.
5. Discussion
Helicobacter pylori is an important human pathogen
around the world. The prevalence of H. pylori infection in
Iran, like other developing countries, is higher than those
in the developed world (16-23). The prevalence of H.pylori
infection in different areas of Iran is variable, ranging from
30.6% to 93.0% (19-21). In this study, the estimated infection
rate was 45%, which is similar to that of other researchers
reported from Tehran (24-26). Antibiotic resistance is the
main reason for treatment failure and persistent infection
of H. pylori in developing countries. The increasing resis-
tance to antibiotics is commonly due to a lack of proper ad-
ministration, inappropriate dosing, arbitrary use of drugs,
and genetic mutations in H. pylori strains (27, 28). Metron-
idazole is a common antibiotic used for H. pylori treatment
in Iran, and resistant strains to this antibiotic are becom-
ing a major problem for therapeutic regiments (27). Resis-
tance to metronidazole was raised among H. pylori strains
in Iran from 73.4% in 2009 to 88.2% in 2011 (27). In the
present study found high rates of metronidazole resistant
strains of H. pylori (60%) in the studied hospitals. This resis-
tance rate seems to be associated with historical adminis-
tration of metronidazole for various parasitic and oral cav-
ity infections, since most of the strains were isolated from
patients over 40 years old. While no statistically signifi-
cant change in resistance rate was detected for metronida-
zole in this study, a higher amount of MIC values (MIC50 ≥
64µg/mL vs 32µg/mL) was found compared with previous
studies from Iran (28).
Tetracyclines are other anti-H. pylori antibiotics, which
are used as a component of the quadruple therapy regi-
mens. The extent of resistance towards this drug is also
variable in different areas. This discrepancy may in-part be
due to different sample sizes and the specific antibiogram
method used (18, 19). There are many reports indicating
an increasing trend of resistance towards this antibiotic;
however, resistance rate to this antibiotic is lower than
those described for metronidazole (29-37). Comparison of
MIC50 for doxycycline and metronidazole (4 vs 32 µg/mL)
proposed 8 times higher activity of doxycycline against
metronidazole resistantH. pylori strains. However, nitazox-
anide showed a four-fold greater anti-bacterial property
compared with metronidazole, based on its MIC50 value. It
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Table 1. Diversity of Minimum Inhibitory Concentration Values of Nitazoxanide and Doxycycline for Different Metronidazole Resistant Helicobacter pylori Strainsa
Metronidazole,µg/mL Nitazoxanide,µg/mL Doxycycline,µg/mL Total
1 2 4 8 16 ≥32 1 2 4 ≥8
16 0 1 1 3 1 4 1 2 2 5 10 (30.3)
32 0 2 3 3 1 5 3 0 4 7 14 (42.5)
64 1 0 3 2 1 2 1 4 1 3 9 (27.2)
Total 1 (3) 3 (9) 7 (21.3) 8 (24.4) 3 (9) 11 (33.3) 5 (12.5) 10 (25) 9 (22.5) 16 (40) 33 (100)
a Values are expressed as No. (%).
Figure 1. Correlation of Minimal Inhibitory Concentrations of Metronidazole, Doxycycline, and Nitazoxanide in Metronidazole Resistant Helicobacter pylori Stains
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could therefore be suggested that these 2 drugs were supe-
rior in their ability to inhibit growth of H. pylori in compar-
ison to metronidazole. There are a few studies on the activ-
ity of doxycycline and nitazoxanide against metronidazole
resistant strains. In a study by Cammarota et al. in Italy, su-
perior effects of doxycycline-based quadruple regimen for
eradication of metronidazole resistant H. pylori infection,
with MIC range of 0.056 to 1µg/mL and MIC50 and MIC90 of
0.125 and 0.5 µg/mL, was presented (38). The MIC range of
0.25 to 8.0 µg/mL for doxycycline and MIC50 and MIC90 of
0.5 and 2 was also reported for clinical isolates of H. pylori
in Canada (39). Results of the current study showed higher
MIC ranges for this antibiotic (MIC range of 1 to≥8.0µg/mL
and MIC50 and MIC90 of 4 and≥8), which suggests greater
consideration for its administration to prevent emergence
of more resistant strains in Iran. In case of nitazoxanide,
Megraud F. et al reported MIC range of 0.25 to 8µg/mL, with
MIC50 and MIC90 of 1 and 4, among metronidazole resistant
and susceptible strains (0.25- >32, MIC50 and MIC90 2 and
>32µg/mL) (40). In a study from Australia, MIC range of ni-
tazoxanide varied between 0.06 and 4µg/mL (41). Likewise,
these MIC ranges were lower than those detected in Iran.
However, they observed no significant change in MIC levels
after nitazoxanide administration compared with metron-
idazole, and its higher activity against H. pylori strains sug-
gests its preference for clinical usage.
Lack of association between MIC values of metronida-
zole and those from nitazoxanide or doxycycline could be
explained by diversity of resistance mechanisms to these
drugs (35). Although the current results provide some evi-
dence about preferred activity of nitazoxanide and doxycy-
cline, further studies are needed to investigate their usage
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Figure 2. Correlation Between Minimum Inhibitory Concentration Values of Antibiotics and Pathological Findings
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p value, 0.395 for metronidazole; P value, 0.573 for doxycycline; P value, 0.486 for nitazoxanide. CG, Chronic Gastritis; SAG, Severe Active Gastritis; GU, Gastric Ulcer; R, Reflux.
against metronidazole resistance H. pylori strains.
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